Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D1NDO8
|
|||
| Drug Name |
Efavaleukin alfa
|
|||
| Synonyms |
AMG592
Click to Show/Hide
|
|||
| Drug Type |
Fusion Protein
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [1] | |
| Ulcerative colitis [ICD-11: DD71; ICD-9: 556] | Phase 2 | [2] | ||
| Company |
Amgen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04680637) A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04987307) A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.